Dick’s Pullback RAISES Target and 4 Stock Analyst Notes
Gilead Sciences Inc. (NASDAQ:GILD): Deutsche Bank believes that the FDA will approve Gilead’s Quad on August 27 due to the positive panel vote in May and because the U.S. HIV treatment guidelines are already adding the drug. Deutsche believes that Gilead will be able beat consensus launch expectations, and it increased its price target for shares to $68 from $65 while it maintained a Buy rating on the stock.
Don’t Miss: These Retailers Are Going MOBILE.
Liberty Media (NASDAQ:LMCA) price target was increased by Deutsche Bank because of the rise in Sirius XM (NASDAQ:SIRI) shares along with a higher Starz valuation. The firm thinks that Liberty Media has become a simple entity, and it reiterates a Buy rating on the stock.
Dick’s Sporting Goods Inc. (NYSE:DKS): According to Citigroup, the pullback in shares of Dick’s Sporting after the company’s Q2 results create a buying opportunity. The firm increased its price target for shares to $58 from $57, and it maintains a Buy rating on the stock.
Towers Watson & Co. (NYSE:TW): Citigroup thinks that the 12 percent pullback in Towers Watson shares yesterday after the company’s Q4 results creates a good buying opportunity. Citi claims that a great deal of the revenue slowdown that was implied by the company’s Q1 guidance is because of short-term timing issues, and it maintains a Buy rating on the stock. The firm reduced its price target to $65 from $75 on the stock.
Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) was added to Roth Capital’s Focus List as a Top Biotech Pick, and it believes that shares will move higher as a result of an expected strong survival update from the 2nd line NSCLC study on September 7. Shares have a Buy rating and a $5 price target.
Don’t Miss: Is This the GROWTH ENGINE Apple’s Quarter Needs?
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.